SCM
Silverarc Capital Management Portfolio holdings
AUM
$962M
Turnover
51.02%
1-Year Est. Return
524.65%
This Fund
S&P 500
This Quarter
Est. Return
+60.76%
1 Year Est. Return
+524.65%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.09%
10 Year Est. Return
–
AUM
$323M
AUM Growth
+$81M
(+33%)
Cap. Flow
+$40.9M
Cap. Flow
% of AUM
12.64%
Top 10 Holdings %
Top 10 Hldgs %
43.73%
Holding
97
New
25
Increased
29
Reduced
18
Closed
15
Avg Time Held Equity + Options
0.7
years
Top 10 Avg Time Held Equity + Options
0.2
years
Top 20 Avg Time Held Equity + Options
0.3
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Immunogen Inc
IMGN
|
+$15M |
| 2 |
Morphic Holding, Inc. Common Stock
MORF
|
+$10.5M |
| 3 |
Krystal Biotech
KRYS
|
+$8.67M |
| 4 |
Biogen
BIIB
|
+$4.63M |
| 5 |
Intra-Cellular Therapies Inc.
ITCI
|
+$4.59M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BLU
BELLUS Health Inc.
BLU
|
+$7.2M |
| 2 |
Nuvalent
NUVL
|
+$6.29M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$4.11M |
| 4 |
Pharvaris
PHVS
|
+$3.48M |
| 5 |
Karyopharm Therapeutics
KPTI
|
+$2.94M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.54% |
| 2 | Miscellaneous | 8.39% |
| 3 | Consumer Staples | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
DELISTED
Immunogen Inc
IMGN
| $26.8M | 8.29% |
1,420,000
+1,270,000
| +847% | +$15M |
2020 Q4
10 quarters
|
|
2
DELISTED
Merus
MRUS
| $15.5M | 4.8% |
589,255
-79,529
| -12% | -$1.74M |
2021 Q1
9 quarters
|
|
|
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $14.5M | 4.47% |
252,309
+200,625
| +388% | +$10.5M |
2020 Q4
10 quarters
|
|
4
Schrodinger
SDGR
$1.87B
| $14.3M | 4.42% |
286,169
+73,344
| +34% | +$2.48M |
2022 Q4
2 quarters
|
|
|
5
Krystal Biotech
KRYS
$9.79B
| $14M | 4.32% |
118,941
+84,927
| +250% | +$8.67M |
2021 Q4
6 quarters
|
|
|
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $12.6M | 3.89% |
198,723
+73,688
| +59% | +$4.59M |
2020 Q4
10 quarters
|
|
7
DELISTED
Akero Therapeutics
AKRO
| $11.3M | 3.49% |
241,357
+38,796
| +19% | +$1.78M |
2022 Q2
4 quarters
|
|
8
Oric Pharmaceuticals
ORIC
$1.2B
| $11.3M | 3.48% |
1,450,822
+14,877
| +1% | +$84.5K |
2022 Q2
4 quarters
|
|
|
9
CALL
DELISTED
Akero Therapeutics
AKRO
| $11M | 3.42% |
+236,500
| New | +$10.8M |
2023 Q2
0 quarters
|
|
10
MoonLake Immunotherapeutics
MLTX
$863M
| $10.2M | 3.16% |
200,000
+94,250
| +89% | +$2.54M |
2023 Q1
1 quarter
|
|
|
11
Biogen
BIIB
$34.4B
| $7.65M | 2.37% |
26,854
+15,543
| +137% | +$4.63M |
2022 Q4
2 quarters
|
|
12
DELISTED
89bio
ETNB
| $7.51M | 2.32% |
396,497
-41,718
| -10% | -$733K |
2023 Q1
1 quarter
|
|
13
Cogent Biosciences
COGT
$4.88B
| $7.34M | 2.27% |
620,000
+40,736
| +7% | +$467K |
2020 Q4
10 quarters
|
|
14
CALL
Aclaris Therapeutics
ACRS
$498M
| $6.76M | 2.09% |
651,400
| – | – |
2023 Q1
1 quarter
|
|
15
United Therapeutics
UTHR
$23.2B
| $6.63M | 2.05% |
30,029
+11,451
| +62% | +$2.54M |
2020 Q4
10 quarters
|
|
16
MacroGenics
MGNX
$211M
| $6.5M | 2.01% |
1,215,675
-146,134
| -11% | -$901K |
2022 Q3
3 quarters
|
|
17
DELISTED
KalVista Pharmaceuticals
KALV
| $6.48M | 2.01% |
720,508
-3,036
| -0.4% | -$28K |
2023 Q1
1 quarter
|
|
18
Veracyte
VCYT
$3.5B
| $5.84M | 1.81% |
229,451
+19,798
| +9% | +$480K |
2021 Q1
9 quarters
|
|
|
MRTX
19
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5.42M | 1.68% |
+150,000
| New | +$6.18M |
2023 Q2
0 quarters
|
|
20
BioCryst Pharmaceuticals
BCRX
$2.06B
| $5.36M | 1.66% |
760,904
+183,147
| +32% | +$1.47M |
2022 Q1
5 quarters
|
|
21
DELISTED
Terns Pharmaceuticals
TERN
| $5.25M | 1.62% |
599,668
-68,254
| -10% | -$796K |
2022 Q3
3 quarters
|
|
22
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $5.18M | 1.6% |
2,945,948
+256,647
| +10% | +$656K |
2021 Q4
6 quarters
|
|
|
23
DELISTED
Nuvalent
NUVL
| $4.85M | 1.5% |
115,067
-166,466
| -59% | -$6.29M |
2022 Q3
3 quarters
|
|
24
Gilead Sciences
GILD
$190B
| $4.66M | 1.44% |
60,448
+318
| +0.5% | +$25.4K |
2022 Q4
2 quarters
|
|
25
Vertex Pharmaceuticals
VRTX
$126B
| $4.64M | 1.43% |
13,175
-6
| -0% | -$2.02K |
2021 Q4
6 quarters
|
|
Similar funds
LGP
PL
LAM
ACP
GIG
AAP
RAM
JWBC
Silverarc Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Silverarc Capital Management held 97 positions worth $323M, up 33% from $242M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Silverarc Capital Management deployed $40.9M of net new capital in Q2 2023, opening 25 new positions and adding to 29 existing holdings. Its largest new stake was Mirati Therapeutics, Inc. Common Stock: 91,213 shares worth $3.3M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier, followed by Miscellaneous and Consumer Staples.
On the sell side, the largest reduction was Nuvalent, an estimated $6.29M trimmed.
- Silverarc Capital Management's largest Q2 2023 buy was Mirati Therapeutics, Inc. Common Stock: 91,213 shares worth $3.3M.
- Silverarc Capital Management added most to Immunogen Inc in Q2 2023, an estimated $15M increase.
- Silverarc Capital Management's biggest Q2 2023 reduction was Nuvalent, cutting an estimated $6.29M.
- Silverarc Capital Management fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $7.2M.
- Silverarc Capital Management's ten largest holdings make up 44% of its $323M portfolio in Q2 2023.
- Silverarc Capital Management opened 25 new positions and closed 15 in Q2 2023.
- Silverarc Capital Management's portfolio value rose 33% quarter-over-quarter to $323M.
Based on Silverarc Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.